CryoCath Technologies, Inc. recently announced a decision to sell their surgical portfolio to ATS Medical. CryoCath manufactures cryotherapy products for treating cardiac arrhythmias. The transaction will allow the company to focus on its line of electrophysiology products for treating atrial fibrillation and other arrhythmias. In addition to the US$22 million dollar cash transaction, CryoCath will receive an additional US$8 million from milestone payments. “The sale of our surgical business marks a significant milestone in our strategy to transition CryoCath into a focused and fast-growing electrophysiology cryoblation company,” said CryoCath’s President and CEO, Jan Keltjens.
